Company Filing History:
Years Active: 1999
Title: Nam Joong Lee: Innovator in Vaccine Development
Introduction
Nam Joong Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of vaccine development, particularly in relation to Pseudomonas aeruginosa infections. His innovative work has the potential to impact public health positively.
Latest Patents
Nam Joong Lee holds a patent for a process for preparing a vaccine against Pseudomonas aeruginosa. This vaccine is derived from attenuated strains of Pseudomonas aeruginosa, specifically isolated and purified according to the Fisher-Devlin immunotype. The strains involved include CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034), and CFCPA 70018 (KCCM 10035). The vaccine contains cell wall proteins with molecular weights ranging from 10,000 to 100,000, which are non-pathogenic and safe. These proteins exhibit excellent antibody formation capacity and are useful for both vaccine and therapeutic agent preparation.
Career Highlights
Nam Joong Lee is associated with Cheiljedang Corporation, where he continues to work on innovative solutions in the field of biotechnology. His research focuses on developing effective vaccines that can provide immunity against harmful bacterial infections.
Collaborations
Nam Joong Lee has collaborated with notable colleagues, including Hyun Su Kim and Wan Je Park. Their combined expertise contributes to the advancement of vaccine technology and research.
Conclusion
Nam Joong Lee's work in vaccine development showcases his commitment to improving health outcomes through innovative solutions. His contributions are vital in the ongoing fight against bacterial infections, particularly those caused by Pseudomonas aeruginosa.